A BILL 
To amend part D of title XVIII of the Social Security 
Act to deliver a meaningful benefit and lower prescription 
drug prices under the Medicare program. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Medicare Prescription 
4
Drug Savings and Choice Act of 2019’’. 
5
18:56 Oct 28, 2019
H4769
2 
•HR 4769 IH
SEC. 2. ESTABLISHMENT OF MEDICARE OPERATED PRE-
1
SCRIPTION DRUG PLAN OPTION. 
2
(a) IN GENERAL.—Subpart 2 of part D of title XVIII 
3
of the Social Security Act is amended by inserting after 
4
section 1860D–11 (42 U.S.C. 1395w–111) the following 
5
new section: 
6
‘‘MEDICARE OPERATED PRESCRIPTION DRUG PLAN 
7
OPTION 
8
‘‘SEC. 1860D–11A. (a) IN
GENERAL.—Notwith-
9
standing any other provision of this part, for each year 
10
(beginning with 2021), in addition to any plans offered 
11
under section 1860D–11, the Secretary shall offer one or 
12
more Medicare operated prescription drug plans (as de-
13
fined in subsection (d)) with a service area that consists 
14
of the entire United States and shall enter into negotia-
15
tions in accordance with subsection (c) with pharma-
16
ceutical manufacturers to reduce the purchase cost of cov-
17
ered part D drugs for eligible part D individuals who en-
18
roll in such a plan. 
19
‘‘(b) 
ENROLLMENT.—Notwithstanding 
subpara-
20
graphs (C) and (D) of section 1860D–1(b)(1), a Medicare 
21
operated prescription drug plan offered under this section 
22
shall serve as the default prescription drug plan for all 
23
part D enrollees unless another prescription drug plan is 
24
selected. 
25
18:56 Oct 28, 2019
H4769
3 
•HR 4769 IH
‘‘(c) 
NEGOTIATIONS.—Notwithstanding 
section 
1
1860D–11(i), for purposes of offering a Medicare operated 
2
prescription drug plan under this section, the Secretary 
3
shall negotiate with pharmaceutical manufacturers with 
4
respect to the purchase price of covered part D drugs in 
5
a Medicare operated prescription drug plan and shall en-
6
courage the use of more affordable therapeutic equivalents 
7
to the extent such practices do not override medical neces-
8
sity as determined by the prescribing physician. To the 
9
extent practicable and consistent with the previous sen-
10
tence, the Secretary shall implement negotiation and in-
11
centive strategies similar to those used by other Federal 
12
purchasers of prescription drugs to reduce the purchase 
13
cost of covered Part D drugs, and other strategies, as de-
14
scribed in subsection (f), which may include the use of a 
15
pricing scale based on an international price index. 
16
‘‘(d) MEDICARE OPERATED PRESCRIPTION DRUG 
17
PLAN DEFINED.—For purposes of this part, the term 
18
‘Medicare operated prescription drug plan’ means a com-
19
prehensive prescription drug plan that offers qualified pre-
20
scription drug coverage and access to negotiated prices de-
21
scribed in section 1860D–2(a)(1)(A). Such a plan may 
22
offer supplemental prescription drug coverage in the same 
23
manner as other qualified prescription drug coverage of-
24
fered by other prescription drug plans. 
25
18:56 Oct 28, 2019
H4769
4 
•HR 4769 IH
‘‘(e) MONTHLY BENEFICIARY PREMIUM.— 
1
‘‘(1) QUALIFIED
PRESCRIPTION
DRUG
COV-
2
ERAGE.—The monthly beneficiary premium for 
3
qualified prescription drug coverage and access to 
4
negotiated prices described in section 1860D– 
5
2(a)(1)(A) to be charged under a Medicare operated 
6
prescription drug plan shall be uniform nationally. 
7
Such premium for months in 2021 and each suc-
8
ceeding year shall be based on the average monthly 
9
per capita actuarial cost of offering the Medicare op-
10
erated prescription drug plan for the year involved, 
11
including administrative expenses. 
12
‘‘(2) SUPPLEMENTAL PRESCRIPTION DRUG COV-
13
ERAGE.—Insofar as a Medicare operated prescrip-
14
tion drug plan offers supplemental prescription drug 
15
coverage, the Secretary may adjust the amount of 
16
the premium charged under paragraph (1). 
17
‘‘(f) USE OF NEGOTIATION AND BENEFIT DESIGN 
18
INCENTIVES.— 
19
‘‘(1) IN GENERAL.—With respect to the oper-
20
ation of a Medicare operated prescription drug plan 
21
and in negotiating with respect to the purchase price 
22
of covered part D drugs in such plan, the Secretary 
23
shall reward value, increase appropriate use of 
24
18:56 Oct 28, 2019
H4769
5 
•HR 4769 IH
drugs, and ensure patient safety and access to medi-
1
cations. 
2
‘‘(2) ROLE
OF
AHRQ.—The Director of the 
3
Agency for Healthcare Research and Quality, in co-
4
ordination with the Administrator of the Centers for 
5
Medicare & Medicaid Services, shall be responsible 
6
for assessing the clinical benefit of covered part D 
7
drugs and making recommendations to the Secretary 
8
regarding the negotiated prices of covered drugs and 
9
any appropriate tiering or incentive strategies under 
10
the plan. In conducting such assessments and mak-
11
ing such recommendations, the Director shall carry 
12
out the following activities: 
13
‘‘(A) 
Consider 
the 
comparable 
inter-
14
national price of such drugs based upon the me-
15
dian retail list price of such drug (which shall 
16
be, as practicable, the volume-weighted price for 
17
comparable units and dosage forms) among a 
18
category of at least the following peer reference 
19
countries: 
Canada, 
the 
United 
Kingdom, 
20
France, Japan, Australia, and Germany. 
21
‘‘(B) Consider safety concerns and post- 
22
market data, including those identified by the 
23
Food and Drug Administration and from na-
24
tional health registries. 
25
18:56 Oct 28, 2019
H4769
6 
•HR 4769 IH
‘‘(C) Use available data and evaluations, 
1
including from research supported by the Na-
2
tional Institutes of Health, with priority given 
3
to randomized controlled trials, to examine clin-
4
ical effectiveness, comparative effectiveness, 
5
safety, and enhanced compliance with a drug 
6
regimen. 
7
‘‘(D) Use the same classes of drugs devel-
8
oped by United States Pharmacopeia for this 
9
part. 
10
‘‘(E) Consider evaluations made by— 
11
‘‘(i) the Director under section 1013 
12
of the Medicare Prescription Drug, Im-
13
provement, and Modernization Act of 
14
2003; 
15
‘‘(ii) other Federal entities, such as 
16
the Secretary of Veterans Affairs; and 
17
‘‘(iii) other private and public entities, 
18
which may include the Drug Effectiveness 
19
Review Project and Medicaid programs. 
20
‘‘(F) Consider recommendations made by 
21
the advisory committee pursuant to paragraph 
22
(3)(F). 
23
‘‘(G) Recommend to the Secretary those 
24
drugs in a class that provide a greater clinical 
25
18:56 Oct 28, 2019
H4769
7 
•HR 4769 IH
benefit, including fewer safety concerns or less 
1
risk of side-effects, than another drug in the 
2
same class. 
3
‘‘(3) USE OF ADVISORY COMMITTEE.— 
4
‘‘(A) IN
GENERAL.—The Secretary shall 
5
establish and appoint an advisory committee (in 
6
this paragraph referred to as the ‘advisory com-
7
mittee’)— 
8
‘‘(i) to review petitions from drug 
9
manufacturers, health care provider orga-
10
nizations, patient groups, and other enti-
11
ties regarding negotiated prices; and 
12
‘‘(ii) to recommend any changes in 
13
order to further negotiations with respect 
14
to such prices. 
15
‘‘(B) COMPOSITION.—Subject to subpara-
16
graph (C), the advisory committee shall be com-
17
posed of 9 members and shall include represent-
18
atives of physicians, pharmacists, consumers, 
19
and others with expertise in evaluating prescrip-
20
tion drugs. The Secretary shall select members 
21
based on their knowledge of pharmaceuticals 
22
and the Medicare population. Members shall be 
23
deemed to be special Government employees for 
24
purposes of applying the conflict of interest pro-
25
18:56 Oct 28, 2019
H4769
8 
•HR 4769 IH
visions under section 208 of title 18, United 
1
States Code, and no waiver of such provisions 
2
for such a member shall be permitted. 
3
‘‘(C) BANNED INDIVIDUALS.— 
4
‘‘(i) DRUG COMPANY LOBBYISTS.—No 
5
former registered drug manufacturer lob-
6
byist— 
7
‘‘(I) may be appointed to the ad-
8
visory committee; or 
9
‘‘(II) may be employed by the ad-
10
visory committee during the 6-year 
11
period beginning on the date on which 
12
the registered lobbyist terminates its 
13
registration in accordance with section 
14
4(d) of the Lobbying Disclosure Act 
15
of 1995 (2 U.S.C. 1603(d)) or the 
16
agent terminates its status, as appli-
17
cable. 
18
‘‘(ii) SENIOR
EXECUTIVES
OF
LAW- 
19
BREAKING COMPANIES.—No former senior 
20
executive of a covered entity (as defined in 
21
clause (iii))— 
22
‘‘(I) may be appointed to the Ad-
23
visory Committee; or 
24
18:56 Oct 28, 2019
H4769
9 
•HR 4769 IH
‘‘(II) may be employed by the 
1
Advisory Committee during the 6-year 
2
period beginning on the later of— 
3
‘‘(aa) the date of the settle-
4
ment described in item (aa) of 
5
clause (iii)(II); or 
6
‘‘(bb) the date on which the 
7
enforcement action described in 
8
item (bb) of such clause has con-
9
cluded. 
10
‘‘(iii) COVERED
ENTITY.—The term 
11
‘covered entity’ means any entity that is— 
12
‘‘(I) a drug manufacturer; and 
13
‘‘(II)(aa) operating under Fed-
14
eral settlement including a Federal 
15
consent decree; or 
16
‘‘(bb) the subject of an enforce-
17
ment action in a court of the United 
18
States or by an agency. 
19
‘‘(D) CONSULTATION.—The advisory com-
20
mittee shall consult, as necessary, with physi-
21
cians who are specialists in treating the disease 
22
for which a drug is being considered. 
23
‘‘(E) REQUEST FOR STUDIES.—The advi-
24
sory committee may request the Agency for 
25
18:56 Oct 28, 2019
H4769
10 
•HR 4769 IH
Healthcare Research and Quality or an aca-
1
demic or research institution to study and make 
2
a report on a petition described in subpara-
3
graph (A)(i) in order to assess cost-effective-
4
ness, clinical effectiveness, comparative effec-
5
tiveness, safety, and compliance with a drug 
6
regimen. 
7
‘‘(F) RECOMMENDATIONS.—The advisory 
8
committee shall make recommendations to the 
9
Director of the Agency for Healthcare Research 
10
and Quality regarding the appropriate price at 
11
which to begin negotiations on a part D drug 
12
pursuant to this section. 
13
‘‘(G) LIMITATIONS ON REVIEW OF MANU-
14
FACTURER
PETITIONS.—The advisory com-
15
mittee shall not review a petition of a drug 
16
manufacturer under subparagraph (A)(i) with 
17
respect to a covered part D drug unless the pe-
18
tition is accompanied by the following: 
19
‘‘(i) Raw data from clinical trials on 
20
the safety and effectiveness of the drug. 
21
‘‘(ii) Any data from clinical trials con-
22
ducted using active controls on the drug or 
23
drugs that are the current standard of 
24
care. 
25
18:56 Oct 28, 2019
H4769
11 
•HR 4769 IH
‘‘(iii) Any available data on compara-
1
tive effectiveness of the drug. 
2
‘‘(iv) Any other information the Sec-
3
retary requires for the advisory committee 
4
to complete its review. 
5
‘‘(g) INFORMING BENEFICIARIES.—The Secretary 
6
shall take steps to inform part D eligible individuals not 
7
previously enrolled in a Medicare operated drug plan (in-
8
cluding such individuals who are newly eligible to enroll 
9
under this part) regarding the enrollment of such indi-
10
vidual in a Medicare operated drug plan in accordance 
11
with this section, including providing information in the 
12
annual handbook and adding information to the official 
13
public Medicare website related to prescription drug cov-
14
erage available through this part. 
15
‘‘(h) APPLICATION OF ALL OTHER REQUIREMENTS 
16
FOR PRESCRIPTION DRUG PLANS.—Except as specifically 
17
provided in this section, any Medicare operated drug plan 
18
shall meet the same requirements as apply to any other 
19
prescription drug plan, including the requirements of sec-
20
tion 1860D–4(b)(1) relating to assuring pharmacy ac-
21
cess.’’. 
22
(b) CONFORMING AMENDMENTS.— 
23
18:56 Oct 28, 2019
H4769
12 
•HR 4769 IH
(1) Section 1860D–3(a) of the Social Security 
1
Act (42 U.S.C. 1395w–103(a)) is amended by add-
2
ing at the end the following new paragraph: 
3
‘‘(4) AVAILABILITY OF THE MEDICARE OPER-
4
ATED PRESCRIPTION DRUG PLAN.—A Medicare op-
5
erated prescription drug plan (as defined in section 
6
1860D–11A(d)) shall be offered nationally in ac-
7
cordance with section 1860D–11A.’’. 
8
(2)(A) Section 1860D–3 of the Social Security 
9
Act (42 U.S.C. 1395w–103) is amended by adding 
10
at the end the following new subsection: 
11
‘‘(c) PROVISIONS
ONLY
APPLICABLE
IN
2006 
12
THROUGH 2020.—The provisions of this section shall only 
13
apply with respect to 2006 through 2020.’’. 
14
(B) Section 1860D–11(g) of such Act (42 
15
U.S.C. 1395w–111(g)) is amended by adding at the 
16
end the following new paragraph: 
17
‘‘(8) NO
AUTHORITY
FOR
FALLBACK
PLANS 
18
AFTER 2020.—A fallback prescription drug plan shall 
19
not be available after December 31, 2020.’’. 
20
(3) Section 1860D–13(c)(3) of the Social Secu-
21
rity Act (42 U.S.C. 1395w–113(c)(3)) is amended— 
22
(A) in the heading, by inserting ‘‘AND 
23
MEDICARE
OPERATED
PRESCRIPTION
DRUG 
24
PLANS’’ after ‘‘FALLBACK PLANS’’; and 
25
18:56 Oct 28, 2019
H4769
13 
•HR 4769 IH
(B) by inserting ‘‘or a Medicare operated 
1
prescription drug plan’’ after ‘‘a fallback pre-
2
scription drug plan’’. 
3
(4) Section 1860D–16(b)(1) of the Social Secu-
4
rity Act (42 U.S.C. 1395w–116(b)(1)) is amended— 
5
(A) in subparagraph (C), by striking 
6
‘‘and’’ after the semicolon at the end; 
7
(B) in subparagraph (D), by striking the 
8
period at the end and inserting ‘‘; and’’; and 
9
(C) by adding at the end the following new 
10
subparagraph: 
11
‘‘(E) payments for expenses incurred with 
12
respect to the operation of Medicare operated 
13
prescription drug plans under section 1860D– 
14
11A.’’. 
15
(5) Section 1860D–41(a) of the Social Security 
16
Act (42 U.S.C. 1395w–151(a)) is amended by add-
17
ing at the end the following new paragraph: 
18
‘‘(19) MEDICARE
OPERATED
PRESCRIPTION 
19
DRUG PLAN.—The term ‘Medicare operated prescrip-
20
tion drug plan’ has the meaning given such term in 
21
section 1860D–11A(d).’’. 
22
(c) RULE OF CONSTRUCTION.—Nothing in this sec-
23
tion shall be interpreted to supersede any other negotia-
24
18:56 Oct 28, 2019
H4769
14 
•HR 4769 IH
tion authority granted to the Secretary under Federal law 
1
with respect to prescription drug prices. 
2
SEC. 3. IMPROVED APPEALS PROCESS UNDER THE MEDI-
3
CARE OPERATED PRESCRIPTION DRUG PLAN. 
4
Section 1860D–4(h) of the Social Security Act (42 
5
U.S.C. 1305w–104(h)) is amended by adding at the end 
6
the following new paragraph: 
7
‘‘(4) APPEALS PROCESS FOR MEDICARE OPER-
8
ATED PRESCRIPTION DRUG PLAN.— 
9
‘‘(A) IN
GENERAL.—The Secretary shall 
10
develop a well-defined process for appeals for 
11
denials of benefits under this part under the 
12
Medicare operated prescription drug plan (as 
13
defined in section 1860D–11A(d)). Such proc-
14
ess shall be efficient, impose minimal adminis-
15
trative burdens, and ensure the timely procure-
16
ment of medications. Medical necessity shall be 
17
based on professional medical judgment, the 
18
medical condition of the beneficiary, and other 
19
medical evidence. 
20
‘‘(B) CONSULTATION IN DEVELOPMENT OF 
21
PROCESS.—In developing the appeals process 
22
under subparagraph (A), the Secretary shall 
23
consult with consumer and patient groups, as 
24
well as other key stakeholders, to ensure the 
25
18:56 Oct 28, 2019
H4769
15 
•HR 4769 IH
goals described in subparagraph (A) are 
1
achieved.’’. 
2
Æ 
18:56 Oct 28, 2019
H4769
